Jordan M. Cloyd, MD
Dr. Jordan M. Cloyd is a surgical oncologist at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He cares for patients with gastrointestinal, hepato-pancreatobiliary, neuroendocrine, and peritoneal surface malignancies, including malignant peritoneal mesothelioma. He is skilled in minimally invasive surgical procedures as well as traditional open surgery and is experienced in the use of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery to remove mesothelioma tumors from the peritoneal mesothelioma.[1]
Education and Career
Dr. Cloyd received his medical degree from the University of California San Francisco. He completed his internship and residency in Surgery at Stanford Hospital and Clinics in Palo Alto, California, and completed a fellowship in Surgical Oncology at the MD Anderson Cancer Center in Houston, Texas.[1]
In addition to his surgical role at the James Cancer Hospital, Dr. Cloyd is also an assistant professor in the Division of Surgical Oncology at the Ohio State University Wexner Medical Center.
Research
Dr. Cloyd is a member of the Translational Therapeutics Program at Ohio State University’s Comprehensive Cancer Center. His research investigates the optimal components and sequencing of multimodality therapy using a variety of research methodologies. His goal is the identification of novel clinical and molecular biomarkers that can influence the indications for personalized treatment, as well as to elucidate patient preferences and patient-centered outcomes of multimodality therapy for these cancer types.[1]
Dr. Cloyd has been published in journals including Cancer, JAMA Surgery, and the Journal of Clinical Oncology. His recent publications include:[1]
February 29, 2024 Effect of Behavioral Health Disorders on Surgical Outcomes in Cancer Patients. Katayama ES, Woldesenbet S, Munir MM, Endo Y, Rawicz-Pruszynski K, Khan MMM, Tsilimigras D, Dillhoff M, Cloyd J, Pawlik TM J Am Coll Surg
February 22, 2024 Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma. Brown ZJ, Shannon AH, Cloyd JM Minerva Surg
February 14, 2024 Patient Perceptions of Care Coordination during Neoadjuvant Therapy for Gastrointestinal Cancers: A Mixed Methods Analysis. Bath NM, Palettas M, Stevens L, Sarna A, Ejaz A, Kim A, Pawlik TM, Cloyd JM J Gastrointest Cancer
February 10, 2024 ASO Visual Abstract: Variation in Hospital Mortality After Complex Cancer Surgery-Patient, Volume, Hospital, or Social Determinants? Munir MM, Woldesenbet S, Endo Y, Dillhoff M, Cloyd J, Ejaz A, Pawlik TM Ann Surg Oncol
February 3, 2024 Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative. Fackche NT, Schmocker RK, Nudotor R, Kubi B, Cloyd JM, Grotz TE, Fournier KF, Dineen SP, Veerapong J, Baumgartner JM, Clarke CN, Patel SH, Wilson GC, Lambert LA, Pokrzywa C, Abbott DE, Lee B, Staley CA, Zaidi MY, Johnston FM, Greer JB Ann Surg Oncol
January 31, 2024 Recurrence following Resection of Intraductal Papillary Mucinous Neoplasms: A Systematic Review to Guide Surveillance. Salahuddin A, Thayaparan V, Hamad A, Tarver W, Cloyd JM, Kim AC, Gebhard R, Pawlik TM, Reames BN, Ejaz A J Clin Med
